A	DT	OTHER	O 0 1	[1]	[1]	CAPITALIZED	allAlpha
limitation	NN	NP	O 2 12	[2]	[10]	LOWERCASE	allAlpha
of	IN	PP	O 13 15	[3]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 16 19	[4]	[3]	LOWERCASE	allAlpha
pharmacyte	NN	NP	B-P 20 30	[5]	[10]	LOWERCASE	allAlpha
approach	NN	NP	I-P 31 39	[6]	[8]	LOWERCASE	allAlpha
is	VBZ	VP	O 40 42	[7]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 43 46	[8]	[3]	LOWERCASE	allAlpha
one-time	JJ	NP	O 47 55	[9]	[8]	LOWERCASE	ContainSymbol
nature	NN	NP	O 56 62	[10]	[6]	LOWERCASE	allAlpha
of	IN	PP	O 63 65	[11]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 66 69	[12]	[3]	LOWERCASE	allAlpha
intervention:	NN	NP	O 70 83	[13]	[13]	LOWERCASE	ContainSymbol
ACT	NN	NP	B-M 84 87	[14]	[3]	CAPITALIZED	allAlpha
T-cells	NNS	NP	I-M 88 95	[15]	[7]	CAPITALIZED	ContainSymbol
can	MD	OTHER	O 96 99	[16]	[3]	LOWERCASE	allAlpha
only	RB	OTHER	O 100 104	[17]	[4]	LOWERCASE	allAlpha
be	VB	VP	O 105 107	[18]	[2]	LOWERCASE	allAlpha
loaded	VBN	VP	O 108 114	[19]	[6]	LOWERCASE	allAlpha
once	RB	OTHER	O 115 119	[20]	[4]	LOWERCASE	allAlpha
with	IN	OTHER	O 120 124	[21]	[4]	LOWERCASE	allAlpha
a	DT	OTHER	O 125 126	[22]	[1]	LOWERCASE	allAlpha
cargo	NN	NP	O 127 132	[23]	[5]	LOWERCASE	allAlpha
of	IN	PP	O 133 135	[24]	[2]	LOWERCASE	allAlpha
adjuvant	JJ	NP	B-M 136 144	[25]	[8]	LOWERCASE	allAlpha
drug	NN	NP	I-M 145 149	[26]	[4]	LOWERCASE	allAlpha
prior	RB	OTHER	O 150 155	[27]	[5]	LOWERCASE	allAlpha
to	TO	OTHER	O 156 158	[28]	[2]	LOWERCASE	allAlpha
transfer,	NN	NP	O 159 167	[29]	[9]	LOWERCASE	ContainSymbol
and	CC	OTHER	O 169 172	[30]	[3]	LOWERCASE	allAlpha
the	DT	OTHER	O 173 176	[31]	[3]	LOWERCASE	allAlpha
duration	NN	NP	O 177 185	[32]	[8]	LOWERCASE	allAlpha
of	IN	PP	O 186 188	[33]	[2]	LOWERCASE	allAlpha
stimulation	NN	NP	B-P 189 200	[34]	[11]	LOWERCASE	allAlpha
is	VBZ	VP	O 201 203	[35]	[2]	LOWERCASE	allAlpha
inherently	RB	OTHER	O 204 214	[36]	[10]	LOWERCASE	allAlpha
limited	VBN	VP	O 215 222	[37]	[7]	LOWERCASE	allAlpha
by	IN	PP	O 223 225	[38]	[2]	LOWERCASE	allAlpha
expansion	NN	NP	B-P 226 235	[39]	[9]	LOWERCASE	allAlpha
of	IN	PP	I-P 236 238	[40]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	I-P 239 242	[41]	[3]	LOWERCASE	allAlpha
cell	NN	NP	I-P 243 247	[42]	[4]	LOWERCASE	allAlpha
population	NN	NP	I-P 248 258	[43]	[10]	LOWERCASE	allAlpha
in	IN	PP	I-P 259 261	[44]	[2]	LOWERCASE	allAlpha
vivo,	NN	NP	I-P 262 266	[45]	[5]	LOWERCASE	ContainSymbol
since	IN	PP	O 268 273	[46]	[5]	LOWERCASE	allAlpha
cell-bound	JJ	NP	B-M 274 284	[47]	[10]	LOWERCASE	ContainSymbol
particles	NNS	NP	I-M 285 294	[48]	[9]	LOWERCASE	allAlpha
are	VBP	VP	O 295 298	[49]	[3]	LOWERCASE	allAlpha
diluted	VBN	VP	O 299 306	[50]	[7]	LOWERCASE	allAlpha
with	IN	OTHER	O 307 311	[51]	[4]	LOWERCASE	allAlpha
each	DT	OTHER	O 312 316	[52]	[4]	LOWERCASE	allAlpha
cell	NN	NP	B-M 317 321	[53]	[4]	LOWERCASE	allAlpha
division.	NN	NP	I-P 322 330	[54]	[9]	LOWERCASE	ContainSymbol

We	PRP	OTHER	O 332 334	[1]	[2]	CAPITALIZED	allAlpha
hypothesized	VBD	VP	O 335 347	[2]	[12]	LOWERCASE	allAlpha
that	IN	OTHER	O 348 352	[3]	[4]	LOWERCASE	allAlpha
a	DT	OTHER	O 353 354	[4]	[1]	LOWERCASE	allAlpha
strategy	NN	NP	O 355 363	[5]	[8]	LOWERCASE	allAlpha
to	TO	OTHER	O 364 366	[6]	[2]	LOWERCASE	allAlpha
target	VB	VP	O 367 373	[7]	[6]	LOWERCASE	allAlpha
supporting	VBG	VP	B-M 374 384	[8]	[10]	LOWERCASE	allAlpha
drugs	NNS	NP	I-M 385 390	[9]	[5]	LOWERCASE	allAlpha
to	TO	OTHER	O 391 393	[10]	[2]	LOWERCASE	allAlpha
T-cells	NNS	NP	B-M 394 401	[11]	[7]	CAPITALIZED	ContainSymbol
with	IN	PP	O 402 406	[12]	[4]	LOWERCASE	allAlpha
nanoparticle	NN	NP	B-M 407 419	[13]	[12]	LOWERCASE	allAlpha
drug	NN	NP	I-M 420 424	[14]	[4]	LOWERCASE	allAlpha
carriers	NNS	NP	I-M 425 433	[15]	[8]	LOWERCASE	allAlpha
directly	RB	OTHER	O 434 442	[16]	[8]	LOWERCASE	allAlpha
in	FW	OTHER	O 443 445	[17]	[2]	LOWERCASE	allAlpha
vivo	FW	OTHER	O 446 450	[18]	[4]	LOWERCASE	allAlpha
would	MD	OTHER	O 451 456	[19]	[5]	LOWERCASE	allAlpha
enable	VB	VP	O 457 463	[20]	[6]	LOWERCASE	allAlpha
transferred	VBN	VP	B-M 464 475	[21]	[11]	LOWERCASE	allAlpha
lymphocytes	NNS	NP	I-M 476 487	[22]	[11]	LOWERCASE	allAlpha
to	TO	OTHER	O 488 490	[23]	[2]	LOWERCASE	allAlpha
be	VB	VP	O 491 493	[24]	[2]	LOWERCASE	allAlpha
repeatedly	RB	OTHER	O 494 504	[25]	[10]	LOWERCASE	allAlpha
stimulated	VBN	VP	O 505 515	[26]	[10]	LOWERCASE	allAlpha
with	IN	PP	O 516 520	[27]	[4]	LOWERCASE	allAlpha
supporting	VBG	VP	B-M 521 531	[28]	[10]	LOWERCASE	allAlpha
adjuvant	JJ	NP	I-M 532 540	[29]	[8]	LOWERCASE	allAlpha
drugs,	NN	NP	I-M 541 546	[30]	[6]	LOWERCASE	ContainSymbol
and	CC	OTHER	O 548 551	[31]	[3]	LOWERCASE	allAlpha
thereby	RB	OTHER	O 552 559	[32]	[7]	LOWERCASE	allAlpha
provide	VBP	VP	O 560 567	[33]	[7]	LOWERCASE	allAlpha
continuous	JJ	NP	O 568 578	[34]	[10]	LOWERCASE	allAlpha
supporting	JJ	VP	O 579 589	[35]	[10]	LOWERCASE	allAlpha
signals	NNS	NP	O 590 597	[36]	[7]	LOWERCASE	allAlpha
over	IN	OTHER	O 598 602	[37]	[4]	LOWERCASE	allAlpha
the	DT	OTHER	O 603 606	[38]	[3]	LOWERCASE	allAlpha
prolonged	JJ	NP	O 607 616	[39]	[9]	LOWERCASE	allAlpha
durations	NNS	NP	O 617 626	[40]	[9]	LOWERCASE	allAlpha
that	WDT	OTHER	O 627 631	[41]	[4]	LOWERCASE	allAlpha
might	MD	OTHER	O 632 637	[42]	[5]	LOWERCASE	allAlpha
be	VB	VP	O 638 640	[43]	[2]	LOWERCASE	allAlpha
necessary	JJ	OTHER	O 641 650	[44]	[9]	LOWERCASE	allAlpha
for	IN	PP	O 651 654	[45]	[3]	LOWERCASE	allAlpha
elimination	NN	NP	B-T 655 666	[46]	[11]	LOWERCASE	allAlpha
of	IN	PP	I-T 667 669	[47]	[2]	LOWERCASE	allAlpha
large	JJ	NP	I-T 670 675	[48]	[5]	LOWERCASE	allAlpha
tumor	NN	NP	I-T 676 681	[49]	[5]	LOWERCASE	allAlpha
burdens.	NN	NP	I-T 682 689	[50]	[8]	LOWERCASE	ContainSymbol

Such	JJ	NP	O 691 695	[1]	[4]	CAPITALIZED	allAlpha
“re-arming”	NN	NP	B-P 696 707	[2]	[11]	LOWERCASE	ContainSymbol
of	IN	PP	I-P 708 710	[3]	[2]	LOWERCASE	allAlpha
T-cells	NNS	NP	B-M 711 718	[4]	[7]	CAPITALIZED	ContainSymbol
with	IN	PP	I-P 719 723	[5]	[4]	LOWERCASE	allAlpha
supporting	JJ	NP	B-M 724 734	[6]	[10]	LOWERCASE	allAlpha
drugs	NNS	NP	I-M 735 740	[7]	[5]	LOWERCASE	allAlpha
could	MD	OTHER	O 741 746	[8]	[5]	LOWERCASE	allAlpha
be	VB	VP	O 747 749	[9]	[2]	LOWERCASE	allAlpha
achieved	VBN	VP	O 750 758	[10]	[8]	LOWERCASE	allAlpha
by	IN	PP	O 759 761	[11]	[2]	LOWERCASE	allAlpha
repeated	JJ	NP	O 762 770	[12]	[8]	LOWERCASE	allAlpha
administration	NN	NP	B-P 771 785	[13]	[14]	LOWERCASE	allAlpha
of	IN	PP	I-P 786 788	[14]	[2]	LOWERCASE	allAlpha
targeted	VBN	VP	I-P 789 797	[15]	[8]	LOWERCASE	allAlpha
particles,	NN	NP	I-P 798 807	[16]	[10]	LOWERCASE	ContainSymbol
allowing	VBG	VP	O 809 817	[17]	[8]	LOWERCASE	allAlpha
adoptively-transferred	JJ	NP	B-M 818 840	[18]	[22]	LOWERCASE	ContainSymbol
T-cells	NNS	NP	I-M 841 848	[19]	[7]	CAPITALIZED	ContainSymbol
to	TO	OTHER	O 849 851	[20]	[2]	LOWERCASE	allAlpha
be	VB	VP	O 852 854	[21]	[2]	LOWERCASE	allAlpha
restimulated	VBN	VP	O 855 867	[22]	[12]	LOWERCASE	allAlpha
multiple	JJ	NP	O 868 876	[23]	[8]	LOWERCASE	allAlpha
times	NNS	NP	O 877 882	[24]	[5]	LOWERCASE	allAlpha
directly	RB	OTHER	O 883 891	[25]	[8]	LOWERCASE	allAlpha
in	FW	OTHER	O 892 894	[26]	[2]	LOWERCASE	allAlpha
vivo,	FW	OTHER	O 895 899	[27]	[5]	LOWERCASE	ContainSymbol
while	IN	OTHER	O 901 906	[28]	[5]	LOWERCASE	allAlpha
the	DT	OTHER	O 907 910	[29]	[3]	LOWERCASE	allAlpha
use	NN	NP	O 911 914	[30]	[3]	LOWERCASE	allAlpha
of	IN	PP	O 915 917	[31]	[2]	LOWERCASE	allAlpha
internalizing	VBG	VP	B-M 918 931	[32]	[13]	LOWERCASE	allAlpha
targeting	VBG	VP	I-M 932 941	[33]	[9]	LOWERCASE	allAlpha
ligands	NNS	NP	I-M 942 949	[34]	[7]	LOWERCASE	allAlpha
would	MD	OTHER	O 950 955	[35]	[5]	LOWERCASE	allAlpha
minimize	VB	VP	O 956 964	[36]	[8]	LOWERCASE	allAlpha
the	DT	OTHER	O 965 968	[37]	[3]	LOWERCASE	allAlpha
likelihood	NN	NP	O 969 979	[38]	[10]	LOWERCASE	allAlpha
of	IN	PP	O 980 982	[39]	[2]	LOWERCASE	allAlpha
immune	JJ	NP	O 983 989	[40]	[6]	LOWERCASE	allAlpha
responses	NNS	NP	O 990 999	[41]	[9]	LOWERCASE	allAlpha
against	IN	OTHER	O 1000 1007	[42]	[7]	LOWERCASE	allAlpha
the	DT	OTHER	O 1008 1011	[43]	[3]	LOWERCASE	allAlpha
nanoparticle	NN	NP	B-M 1012 1024	[44]	[12]	LOWERCASE	allAlpha
carrier.	NN	NP	I-M 1025 1032	[45]	[8]	LOWERCASE	ContainSymbol

To	TO	OTHER	O 1034 1036	[1]	[2]	CAPITALIZED	allAlpha
our	PRP$	OTHER	O 1037 1040	[2]	[3]	LOWERCASE	allAlpha
knowledge,	NN	NP	O 1041 1050	[3]	[10]	LOWERCASE	ContainSymbol
only	RB	OTHER	O 1052 1056	[4]	[4]	LOWERCASE	allAlpha
two	CD	OTHER	O 1057 1060	[5]	[3]	LOWERCASE	allAlpha
prior	JJ	NP	O 1061 1066	[6]	[5]	LOWERCASE	allAlpha
studies	NNS	NP	O 1067 1074	[7]	[7]	LOWERCASE	allAlpha
have	VBP	VP	O 1075 1079	[8]	[4]	LOWERCASE	allAlpha
attempted	VBN	VP	O 1080 1089	[9]	[9]	LOWERCASE	allAlpha
to	TO	OTHER	O 1090 1092	[10]	[2]	LOWERCASE	allAlpha
target	VB	VP	O 1093 1099	[11]	[6]	LOWERCASE	allAlpha
nanoparticles	NNS	NP	B-M 1100 1113	[12]	[13]	LOWERCASE	allAlpha
to	TO	OTHER	O 1114 1116	[13]	[2]	LOWERCASE	allAlpha
T-cells	NNS	NP	B-M 1117 1124	[14]	[7]	CAPITALIZED	ContainSymbol
in	FW	OTHER	O 1125 1127	[15]	[2]	LOWERCASE	allAlpha
vivo	FW	OTHER	O 1128 1132	[16]	[4]	LOWERCASE	allAlpha
[17,18].	FW	OTHER	O 1133 1140	[17]	[8]	LOWERCASE	ContainSymbol

In	IN	OTHER	O 1142 1144	[1]	[2]	CAPITALIZED	allAlpha
both	DT	OTHER	O 1145 1149	[2]	[4]	LOWERCASE	allAlpha
of	IN	OTHER	O 1150 1152	[3]	[2]	LOWERCASE	allAlpha
these	DT	OTHER	O 1153 1158	[4]	[5]	LOWERCASE	allAlpha
studies,	NN	NP	O 1159 1166	[5]	[8]	LOWERCASE	ContainSymbol
particles	NNS	NP	O 1168 1177	[6]	[9]	LOWERCASE	allAlpha
were	VBD	VP	O 1178 1182	[7]	[4]	LOWERCASE	allAlpha
targeted	VBN	VP	O 1183 1191	[8]	[8]	LOWERCASE	allAlpha
to	TO	OTHER	O 1192 1194	[9]	[2]	LOWERCASE	allAlpha
T-cells	NNS	NP	B-M 1195 1202	[10]	[7]	CAPITALIZED	ContainSymbol
via	IN	PP	O 1203 1206	[11]	[3]	LOWERCASE	allAlpha
peptide-MHC	JJ	NP	B-M 1207 1218	[12]	[11]	LOWERCASE	ContainSymbol
ligands	NNS	NP	I-M 1219 1226	[13]	[7]	LOWERCASE	allAlpha
that	WDT	OTHER	O 1227 1231	[14]	[4]	LOWERCASE	allAlpha
bind	VBP	VP	O 1232 1236	[15]	[4]	LOWERCASE	allAlpha
to	TO	OTHER	O 1237 1239	[16]	[2]	LOWERCASE	allAlpha
specific	JJ	NP	O 1240 1248	[17]	[8]	LOWERCASE	allAlpha
T-cell	NN	NP	B-M 1249 1255	[18]	[6]	CAPITALIZED	ContainSymbol
receptors.	NN	NP	I-M 1256 1265	[19]	[10]	LOWERCASE	ContainSymbol

However,	JJ	NP	O 1267 1274	[1]	[8]	CAPITALIZED	ContainSymbol
peptide-MHC-functionalized	JJ	NP	B-M 1276 1302	[2]	[26]	LOWERCASE	ContainSymbol
nanoparticles	NNS	NP	I-M 1303 1316	[3]	[13]	LOWERCASE	allAlpha
have	VBP	VP	O 1317 1321	[4]	[4]	LOWERCASE	allAlpha
recently	RB	OTHER	O 1322 1330	[5]	[8]	LOWERCASE	allAlpha
been	VBN	VP	O 1331 1335	[6]	[4]	LOWERCASE	allAlpha
shown	VBN	VP	O 1336 1341	[7]	[5]	LOWERCASE	allAlpha
to	TO	OTHER	O 1342 1344	[8]	[2]	LOWERCASE	allAlpha
deliver	VB	VP	O 1345 1352	[9]	[7]	LOWERCASE	allAlpha
an	DT	OTHER	O 1353 1355	[10]	[2]	LOWERCASE	allAlpha
anergizing/tolerizing	JJ	NP	O 1356 1377	[11]	[21]	LOWERCASE	ContainSymbol
signal	NN	NP	O 1378 1384	[12]	[6]	LOWERCASE	allAlpha
to	TO	OTHER	O 1385 1387	[13]	[2]	LOWERCASE	allAlpha
T-cells	NNS	NP	B-M 1388 1395	[14]	[7]	CAPITALIZED	ContainSymbol
[18,19]	FW	OTHER	O 1396 1403	[15]	[7]	LOWERCASE	ContainSymbol
—	FW	OTHER	O 1404 1405	[16]	[1]	LOWERCASE	ContainSymbol
which	WDT	OTHER	O 1406 1411	[17]	[5]	LOWERCASE	allAlpha
is	VBZ	VP	O 1412 1414	[18]	[2]	LOWERCASE	allAlpha
ideal	JJ	OTHER	O 1415 1420	[19]	[5]	LOWERCASE	allAlpha
for	IN	OTHER	O 1421 1424	[20]	[3]	LOWERCASE	allAlpha
treating	VBG	VP	B-T 1425 1433	[21]	[8]	LOWERCASE	allAlpha
graft	NN	NP	I-T 1434 1439	[22]	[5]	LOWERCASE	allAlpha
rejection	NN	NP	I-T 1440 1449	[23]	[9]	LOWERCASE	allAlpha
or	CC	OTHER	I-T 1450 1452	[24]	[2]	LOWERCASE	allAlpha
autoimmunity,	NN	NP	I-T 1453 1465	[25]	[13]	LOWERCASE	ContainSymbol
but	CC	OTHER	O 1467 1470	[26]	[3]	LOWERCASE	allAlpha
runs	VBZ	VP	O 1471 1475	[27]	[4]	LOWERCASE	allAlpha
counter	RB	OTHER	O 1476 1483	[28]	[7]	LOWERCASE	allAlpha
to	TO	OTHER	O 1484 1486	[29]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 1487 1490	[30]	[3]	LOWERCASE	allAlpha
goals	NNS	NP	O 1491 1496	[31]	[5]	LOWERCASE	allAlpha
of	IN	PP	O 1497 1499	[32]	[2]	LOWERCASE	allAlpha
cancer	NN	NP	B-T 1500 1506	[33]	[6]	LOWERCASE	allAlpha
immunotherapy.	NN	NP	I-T 1507 1520	[34]	[14]	LOWERCASE	ContainSymbol

